Navigation Links
Driven By Product Innovations, the U.S. Drug Delivery Device Market Will Reach Over $4.5 Billion by 2022
Date:8/6/2014

BURLINGTON, Mass., Aug. 6, 2014 /PRNewswire/ -- Decision Resources Group finds that the United States drug delivery device market will grow at a strong rate to reach a value of over $4.5 billion by 2022 (including device costs only). The future of the drug delivery device market is highly dependent on the pharma industry. Because certain types of drugs are only conducive to specific delivery methods, the kinds of new drugs developed will influence the structure of and innovation in the drug delivery market going forward.

Other key findings from Decision Resources Group's coverage of the U.S. drug delivery device market:

  • Injection devices: Injection devices continue to represent the majority of revenues because diabetic patients largely adopt pen injectors over traditional drug delivery methods, such as insulin pumps or syringes. Leading companies Novo Nordisk, Sanofi and Eli Lilly are also developing new versions or more complex pen injectors, which are expected to launch within the next ten years.
  • AFREZZA inhaler: MannKind recently received approval for the AFREZZA inhaler, which is the first inhaler that can deliver insulin. Because drugs delivered via inhalers are absorbed rapidly by the body, this has the potential to disrupt the traditional insulin delivery device markets. Nonetheless, physicians will need more clinical evidence before the AFREZZA inhaler is widely adopted.
  • Active transdermal patches: Within the transdermal patch market, the development of active patches will enable the treatment of more indications by allowing larger molecules to pass through the skin barrier. The approval of Teva's Zecuity migraine patch in January 2013 represented the first active transdermal patch to become available in the United States.

Comments from Decision Resources Group Senior Analyst Carmen Chan:

  • "A number of new technologies are poised to affect the drug delivery device market in the future. For example, microneedle patches are another type of active patch under development with manufacturers focusing on vaccinations and osteoporosis treatment; both aren't commonly treated with current drug delivery devices."
  • "Subcutaneous implants represent another major product innovation because they eliminate the risk of poor patient compliance, which is currently a significant problem with drug delivery. While current implants serve niche markets, products in development will target widespread conditions like diabetes and hernias."

Additional Resources:

  • Carmen Chan has written a Medtech 360 report on this subject entitled US Markets for Drug Delivery Devices 2014.
  • Decision Resources Group's Pharmacor, which provides a commercial outlook on drugs on the market and in development, can be found here.
  • Decision Resources Group's PatientBase, which determines the total patient and drug-treated populations, can be found here.

About Decision Resources Group
Decision Resources Group offers best-in-class, high-value information and insights on critical issues within the healthcare industry. Clients rely on this analysis and data to make informed decisions. Find out more at www.DecisionResourcesGroup.com.

For more information, contact:
Decision Resources Group
Christopher Comfort
781-993-2597
ccomfort@dresourcesgroup.com

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

Logo - http://photos.prnewswire.com/prnh/20130103/MM36768LOGO


'/>"/>
SOURCE Decision Resources Group
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. The Acute Coronary Syndrome 12-Month Posthospital Market Will Double by 2022, Driven by the Uptake of Novel Lipid Modifying Agents
2. Opportunity Exists in the U.S. for Novel Agents in Crohns Disease and Ulcerative Colitis, Owing to Discontinued Use of Leading Anti-TNF Agents Driven by Efficacy Failures
3. The X-Change Corporation To Announce Corporate Name Change Next Week; New Industry-Driven Branding to Commence For Global Activities, Services, Product Lines, and Website
4. X-Change Corp. Delighted with DOJs Historic Shift Toward Non-Interference Within State Cannabis Regulatory Environments; Sees Green Light for Companys Patient-Driven Medical Cannabis Operations Under State Laws
5. The Dyslipidemia Market Will Grow to $31 Billion in 2022, Driven by the Launch of Novel Therapies
6. European Urological Device Market Will Be Driven By Adoption Of New Minimally Invasive Devices
7. W.K. Kellogg Foundation announces Mission Driven Investment in SeeChange Health
8. Food Recalls Driven by Companies Issuing Multiple Recalls in the First Quarter of 2013, According to Latest ExpertRECALL Index
9. The Medical Affairs Function Is a Key Differentiator for Pharma Product Success in Data-Driven Healthcare Market
10. New Telemedicine Market Forecasts Show Software Sales To Reach $2.5 Billion by 2018, Driven by Tablets Like Apples iPad
11. Drug Discovery Technologies Market Soars to $79 billion by 2017, Driven by Innovations in Pipeline and Tools Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... , February 5, 2016 Site ... Today, VoicePower Ltd - The Speech Recognition People, announced their latest ... to improve patient care, reduce turnaround times and to save the ... ,- VoicePower client since 2013 Challenge: --> ... --> - Six doctors ,- Wirral CCG ,- VoicePower ...
(Date:2/4/2016)... , Feb. 4, 2016  Edwards Lifesciences Corporation (NYSE: ... for structural heart disease and critical care monitoring, announced ... repurchase (ASR) agreement with Morgan Stanley & Co. LLC ... repurchase is part of the Company,s previously authorized program ... common stock.  --> ...
(Date:2/4/2016)... , Feb. 4, 2016  SciClone Pharmaceuticals, Inc. ... it has entered into a settlement agreement with ... fully resolving the SEC,s investigation into possible violations ... the terms of the settlement agreement, SciClone has ... including disgorgement, pre-judgment interest and a penalty.  This ...
Breaking Medicine Technology:
(Date:2/5/2016)... ... February 05, 2016 , ... Francisco Canales, ... services in their Napa Valley office. The technique utilizes the body’s own healing ... Canales and Dr. Furnas, are part of only a select few cosmetic surgeons ...
(Date:2/5/2016)... ... ... US Sports Camps , official operators of Nike Yoga Camps, announces ... training. ChildLight Yoga Studio is centrally situated in the picturesque New England city of ... founder Lisa Flynn expresses her excitement, “We are thrilled to be partnering with US ...
(Date:2/5/2016)... ... February 05, 2016 , ... Boar’s Head Brand®, one of ... for this weekend’s Big Game. Take the stress out of your party preparation – ... guests happy at every stage of the game. , “The key to hosting a ...
(Date:2/5/2016)... ... February 05, 2016 , ... ... CitiDent, announces that it is now welcoming orthodontist, Dr. Amanda Cheng, to ... a complete range of oral health care, including general dentistry, cosmetic treatments, periodontics, ...
(Date:2/5/2016)... ... February 05, 2016 , ... On June 9-10, Las ... continuing medical education (CME) event presented by the Association for Comprehensive Care in ... for ACCORD, whose mission is to provide education, tools, and resources to primary ...
Breaking Medicine News(10 mins):